ESSA Pharma Stock Price, News & Analysis (CVE:EPI)

C$3.99
+0.19 (+5.00 %)
(As of 09/22/2019 05:51 AM ET)
Today's Range
C$3.98
Now: C$3.99
C$4.05
50-Day Range
C$2.00
MA: C$3.04
C$3.99
52-Week Range
C$1.90
Now: C$3.99
C$5.50
Volume2,000 shs
Average Volume3,204 shs
Market CapitalizationC$82.84 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-778-3310962

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.35 per share
Book ValueC$0.08 per share

Profitability

Miscellaneous

Employees15
Market CapC$82.84 million
Next Earnings Date12/12/2019 (Estimated)
OptionableOptionable

Receive EPI News and Ratings via Email

Sign-up to receive the latest news and ratings for EPI and its competitors with MarketBeat's FREE daily newsletter.


ESSA Pharma (CVE:EPI) Frequently Asked Questions

What is ESSA Pharma's stock symbol?

ESSA Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "EPI."

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc (CVE:EPI) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.70) EPS for the quarter, beating analysts' consensus estimates of ($0.73) by $0.03. View ESSA Pharma's Earnings History.

When is ESSA Pharma's next earnings date?

ESSA Pharma is scheduled to release their next quarterly earnings announcement on Thursday, December 12th 2019. View Earnings Estimates for ESSA Pharma.

Has ESSA Pharma been receiving favorable news coverage?

News articles about EPI stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. ESSA Pharma earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for ESSA Pharma.

Who are some of ESSA Pharma's key competitors?

What other stocks do shareholders of ESSA Pharma own?

Who are ESSA Pharma's key executives?

ESSA Pharma's management team includes the folowing people:
  • Dr. David Ross Parkinson, Pres, CEO & Director (Age 69)
  • Mr. David S. Wood, Chief Financial Officer (Age 62)
  • Mr. Peter A. Virsik, Exec. VP & COO (Age 48)
  • Dr. Raymond Andersen, CTO, Sec. & Director (Age 72)
  • Dr. Marianne D. Sadar, Chief Scientific Officer & Director (Age 58)

How do I buy shares of ESSA Pharma?

Shares of EPI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is ESSA Pharma's stock price today?

One share of EPI stock can currently be purchased for approximately C$3.99.

How big of a company is ESSA Pharma?

ESSA Pharma has a market capitalization of C$82.84 million. ESSA Pharma employs 15 workers across the globe.View Additional Information About ESSA Pharma.

What is ESSA Pharma's official website?

The official website for ESSA Pharma is http://essapharmaceuticals.com/.

How can I contact ESSA Pharma?

ESSA Pharma's mailing address is 999 Broadway W Suite 720, VANCOUVER, BC V5Z 1K5, Canada. The company can be reached via phone at +1-778-3310962.


MarketBeat Community Rating for ESSA Pharma (CVE EPI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  97
MarketBeat's community ratings are surveys of what our community members think about ESSA Pharma and other stocks. Vote "Outperform" if you believe EPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel